The FEM-PrEP trial took place in four sites in South Africa, Tanzania and Kenya and enrolled 2120 women aged 18 to 35 who were given either tenofovir plus emtricitabine as PrEP or a placebo.
http://www.aidsmap.com/Magical-thinking-FEM-PrEP-trial-may-have-failed-because-participants-used-testing-as-prevention/page/2695635/
http://www.aidsmap.com/Magical-thinking-FEM-PrEP-trial-may-have-failed-because-participants-used-testing-as-prevention/page/2695635/
No comments:
Post a Comment